Vijay Iyengar was appointed Director of Whitehawk Therapeutics, Inc., effective September 9, 2026. As of November 6, 2026, Whitehawk Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 10, 2026, naming 1 appointment (Form 8-K, September 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Whitehawk Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Whitehawk Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Whitehawk Therapeutics, Inc. files it.
Also on the record for Whitehawk Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Fan Yu | 9.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by OrbiMed Advisors LLC | 7.3% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13D/A, by ACUTA CAPITAL PARTNERS, LLC | 9% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D/A, by Avoro Capital Advisors LLC | 19.99% of the class | 5%+ stakes | Source |
| August 25, 2025 | Stake report, Schedule 13G, by Coastlands Capital LP | 5.98% of the class | 5%+ stakes | Source |
| March 18, 2025 | Form D, private offering | $100M sold | Form D page | Source |
Selling to them or working with them? See who runs Whitehawk Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Whitehawk Therapeutics, Inc. and the records around it.
Whitehawk Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Mar 2025
- Who owns it
Companies that share a holder
- ABG Management Ltd. also filed stake reports on 2 other companies: ProMIS Neurosciences Inc. (Feb 2026), Ceribell, Inc. (Dec 2025)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Watch Whitehawk Therapeutics, Inc.
Get an email when Whitehawk Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Whitehawk Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Whitehawk Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Whitehawk Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-10 | In | Director | 2026-09-09 | 8-K, 2026-09-10 |
Who leads Whitehawk Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Vijay Iyengar, appointed, effective 2026-09-09 (filed 2026-09-10).
New leaders reset buying decisions — get the Full Report on Whitehawk Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Whitehawk Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Whitehawk Therapeutics, Inc.Every change, in the filing's words
Appointed: Vijay Iyengar, Director, effective 2026-09-09
On September 9, 2026, the board of directors (the "Board") of Whitehawk Therapeutics, Inc. (the "Company") increased the number of its authorized directors from nine to ten, and appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026.
- Dr. Iyengar was appointed as a Class III director for a term which will expire at the Company's 2029 annual meeting of stockholders, subject to his earlier resignation, death or removal.
- Dr. Iyengar, age 54, served from May 2022 to November 2025 as Executive Vice President, Global Medical Affairs, Product and Partnership Strategy of Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, and served from May 2016 to April 2022 as Executive Vice President, Global Strategy and Corporate Development of Incyte.
- Prior to joining Incyte, from April 2014 to April 2016, Dr. Iyengar was the President of Genoptix Medical Laboratory, a Novartis Company.
- From December 2011 to March 2014, Dr. Iyengar was the Vice President, Rare Diseases Franchise Head at Novartis Oncology and from July 2009 to November 2011, he was the Oncology General Manager of Novartis Greece.
- From October 2007 to June 2009, Dr. Iyengar was the Global Brand Executive Director at Novartis Pharmaceuticals, and from January 2007 to October 2007, he was the Global Brand Senior Director, Oncology at Novartis Pharmaceuticals.
- Dr. Iyengar received his B.S. in Biology from Stanford University and earned his M.D. from Harvard Medical School.
- We believe that Dr. Iyengar is qualified to serve on our Board because of his extensive industry background and experience in the life sciences industry.
Tools for this story
Each opens in a new tab, filled in for Whitehawk Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.